Combination therapies are the cornerstone of cancer treatment. Are you involved in treating cancer patients, researching the biology underlying cancer, or investigating new medications or drug combinations?

If so, consider attending one, two, or all four focused discussions (“micro labs”) co-hosted this September by NCI’s Division of Cancer Biology and IBM Research. The Combination Therapies for Cancer Treatment Micro Labs will bring together experts in cancer biology and treatment to address the biological complexity at the core of combination therapy interventions, with the goal of improving cancer patient outcomes.

Micro Labs Dates and Descriptions*

• September 14, 2021 | Predicting New Combination Therapies and Regimens: Simultaneous Drug Administration | Learn more about predicting the effects of combination therapies with simultaneous drug administration.
• September 17, 2021 | Predicting New Combination Therapies and Regimens: Temporal Administration Considerations | Learn more about temporal administration considerations for combination therapies.
• September 28, 2021 | The Impact of Intra- and Inter-Tumoral Heterogeneity in the Response to Combination Therapy | Learn more about the role of tumor heterogeneity in responses to cancer combination therapies.
• September 30, 2021 | Moving from Experimental Success to Clinical Reality | Glean perspective on the migration from experimental success to clinical reality with cancer combination therapies. 

*All micro labs are scheduled from 11:00 a.m.–2:00 p.m. ET.